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Context: Pituitary hormonal deficiencies in patients with craniopharyngioma may impair their 
bone health.
Objective: To investigate bone health in patients with craniopharyngioma.
Design: Retrospective cross-sectional study.
Setting: Dutch and Swedish referral centers.
Patients: Patients with craniopharyngioma (n = 177) with available data on bone health after a 
median follow-up of 16 years (range, 1-62) were included (106 [60%] Dutch, 93 [53%] male, 84 
[48%] childhood-onset disease).
Main outcome measures: Fractures, dual X-ray absorptiometry-derived bone mineral density 
(BMD), and final height were evaluated. Low BMD was defined as T- or Z-score ≤-1 and very low 
BMD as ≤-2.5 or ≤-2.0, respectively.
Results: Fractures occurred in 31 patients (18%) and were more frequent in men than in 
women (26% vs. 8%, P = .002). Mean BMD was normal (Z-score total body 0.1 [range, -4.1 to 
3.5]) but T- or Z-score ≤-1 occurred in 47 (50%) patients and T-score ≤-2.5 or Z-score ≤-2.0 in 
22 (24%) patients. Men received less often treatment for low BMD than women (7% vs. 18%, 
P = .02). Female sex (OR 0.3, P = .004) and surgery (odds ratio [OR], 0.2; P = .01) were both 
independent protective factors for fractures, whereas antiepileptic medication was a risk factor 
(OR, 3.6; P = .03), whereas T-score ≤-2.5 or Z-score ≤-2.0 was not (OR, 2.1; P = .21). Mean final 
height was normal and did not differ between men and women, or adulthood and childhood-
onset patients.
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Conclusions: Men with craniopharyngioma are at higher risk than women for fractures. In 
patients with craniopharyngioma, a very low BMD (T-score ≤-2.5 or Z-score ≤-2.0) seems not to 
be a good predictor for fracture risk. (J Clin Endocrinol Metab 105: 1–11, 2020)
Key Words:  craniopharyngioma, bone health, fractures, bone mineral density, final height
C raniopharyngioma is a rare tumor in the pituitary region with peak incidences in the age categories 
5 to 9 and 40 to 44 years (1). Age of onset correlates 
highly with tumor histology: the adamantinomatous 
subtype occurs mainly in childhood, and in adulthood, 
while the papillary subtype almost exclusively occurs at 
adult age (2). The pathogenesis of the 2 subtypes differs 
as well because adamantinomatous craniopharyngioma 
is driven by somatic mutations in CTNNB1, whereas 
the papillary subtypes harbor BRAFV600E mutations 
(2). Craniopharyngioma patients (CP) require extensive 
long-term follow-up because the survival rate is rela-
tively high and the patients often suffer from multiple 
comorbidities (1, 3). Several comorbidities could give 
CP an increased risk of fractures, osteoporosis, and re-
duced growth: CP are at risk of pituitary insufficiency 
and/or possibly nonphysiological replacement therapy 
(3–9), visual deficiency (10), late puberty induction, 
hypothalamic damage, and limited physical activity 
(11–14). In addition, chronic neurological disease is 
associated with clumsiness and high incidence of falls 
(15, 16). Moreover, antiepileptic therapy may even con-
tribute more to the lifetime fracture risk than the seizures 
themselves (17). All of these factors may influence bone 
health and could result in osteoporosis. Osteoporosis is 
a systemic disease characterized by 3 elements: loss of 
bone mass, deterioration of the microarchitecture of the 
bone, and an increased fracture risk (18). Fractures may 
cause chronic pain, disability, and need for rehabilita-
tion (18).
Despite the knowledge of these frequent occurring 
comorbidities, studies addressing fracture risk and 
osteoporosis or bone mineral density (BMD) in CP are 
scarce. Previously found frequencies of fractures were 
higher compared with matched populations and lie be-
tween 15% and 25% (19–21). Olsson et al. described 
an increased risk of fractures with a standardized inci-
dence rate of 2.1 in a large cohort of Swedish CP (1). No 
studies have yet extensively investigated risk factors for 
fractures in CP.
In foregoing research regarding BMD, very few 
adulthood-onset (AO) patients were included: osteo-
porotic/osteopenic BMD values were found in 6 of 10 
and 5 of 6 cases, respectively (22, 23). The studies re-
garding childhood-onset (CO) CP are slightly larger 
but led to different conclusions regarding the influence 
of gender on the risk of fracture (11, 24); Müller et al. 
found that men were at risk for lower volumetric BMD 
(n = 61) (24), whereas Holmer et al. found a low BMD 
in women (n = 39) (11).
Only a few studies have addressed final height, mainly 
in CO CP. In these studies, CO CP reach slightly below 
average or normal final height (19, 25–33).
In summary, information on bone health in CP is 
scarce and contradictory. Also, factors predicting in-
creased risk of fractures in patients with CP have not yet 
been studied. To improve long-term care and increase 
knowledge of possible risk factors of impaired bone 
health in CP, we investigated bone fractures, BMD, and 
final height in a large CP cohort.
Design and Methods
In this retrospective cross-sectional study, CO and AO 
CP treated at the Erasmus University Medical Center 
(Rotterdam, the Netherlands)/Sophia Children’s 
Hospital (Rotterdam, the Netherlands), and Sahlgrenska 
University Hospital (Gothenburg, Sweden) were in-
cluded. Data were collected as previously described (10, 
34). Subjects were included if data were available on 
fractures, dual X-ray absorptiometry (DXA) scan re-
sults for BMD, or on final height.
Data on fractures were acquired as described previ-
ously (10); data on fractures were included from 1987 
until April 2019. Data regarding fractures from the 
Dutch patients concern both inpatient and outpatient 
data; for the Swedish patients, data until 2014 concern 
only inpatient data. If only the year of fracture was 
known, the first of January was used as date to calculate 
age at fracture. Medication to improve BMD was de-
fined as current or past use of bisphosphonates, vitamin 
D, or calcium. Gonadal axis replacement therapy or 
other hormonal replacement therapy was not included 
because the indication of treating pituitary deficien-
cies was broader than only improving BMD and not 
solely for preservation of bone health. The definition 
of hypothalamic damage was described before: it con-
cerns tumor- and/or treatment-related injury to the 
hypothalamus and/or third ventricle as visualized by 
neuroimaging (34). The research proposal was accepted 
by the Ethical Review Board of the Erasmus Medical 
Center and the Regional Ethical Review Board of the 
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Gothenborg University; all patients gave informed 
consent.
All types of DXA scanners were accepted in the ana-
lysis and include Lunar DPXL, Lunar iDXA, and Lunar 
Prodigy. A list of accepted DXA scanners is shown in 
all Supplementary Tables are available at DANS on-
line digital research repository (35). For the current 
study, low BMD was defined as T- or Z-score below 
-1. Osteoporosis was defined as T-score below -2.5 
or Z-score below -2. Osteopenia was defined as T- or 
Z-score between -1 and -2.5 or -2, respectively. If it is 
not specified in the text whether low BMD, osteopenia, 
or osteoporosis are based on T- or Z-score, or on which 
site, it was found to exceed the limit of either T- or 
Z-score, and was measured at the location of femur 
neck, L2-L4, and/or total body (36). If multiple DXA 
scans were performed, the most recent was chosen. The 
decision to perform a DXA scan was made clinically by 
the physician treating the patient.
Final height was defined as the highest measured 
value, after the age of 18 years. Standardized deviation 
scores (SDS) or final height for Dutch subjects were cal-
culated based on requested data with references from 
the Dutch National Statistics (“Centraal Bureau voor 
Statistiek”) (37) based on age, sex, and year of measure-
ment (available on request).
If final height was measured before 1981 or after 
2017, references of 1981 or 2017, respectively, were 
used in Dutch subjects. Final height SDS of Swedish 
subjects was calculated with references of the same sex 
compared with young adults with birth year matched as 
closely as possible (38–40).
Statistical analysis
Statistical analysis was performed with IBM SPSS 
Statistics for Windows, version 24.0, and GraphPad, 
version 8.01. Data are presented as mean and SD unless 
stated otherwise. Significance was accepted if P ≤ .05. 
For normally distributed data, an unpaired t-test was 
used for group comparisons, whereas a Mann-Whitney 
U test was used for nonnormally distributed data. 
Comparisons of proportions were conducted using 
either the χ 2 test or the Fisher exact test as indicated; in 
case of comparison of 2 related dichotomous variables, 
McNemar test was applied. To identify influencing fac-
tors of low BMD at last DXA scan and fractures, a 
univariable logistic regression model was primarily per-
formed; only significant predictors (P < .05) were entered 
in the multiple logistic regression analysis thereafter. If 
the number of events allowed it, the multiple logistic 
regression model was refined by adding variables with 
P < .20. If more variables were significant in univariable 
analysis than could be entered in multivariable model 
because of the size of the cohort, the most significant 
variables were selected in multivariable analysis. If the 
options were comparable, the variable contributing 
to the best discrimination and highest Nagelkerke R2 
was chosen. The dependent variables were studied with 
forced entry. For fractures, a Cox regression model was 
established with the apparent main predictors from 
the logistic regression model. The assumption of pro-
portional hazards was verified by a goodness-of-fit test 
with Schoenfeld residuals and time and checking signifi-
cance of time-dependent covariates. The Wilcoxon rank 
sum test was used to compare nonnormally distributed 
variables and the Student t-test was used for normally 
distributed variables. A 2-way ANOVA was applied for 
comparisons of multiple groups. The incidence rate was 
calculated as total incidence of fractures divided by the 
cumulative follow-up years and multiplied by 1000 to 
calculate the fracture rate per 1000 person-years.
Results
Baseline characteristics
Baseline characteristics of the 177 CP are depicted 
in Table 1 and (35). Data were available on DXA scan 
results for 117 patients and on final height for 171 
patients. Patients with a DXA scan available had a 
higher percentage of diabetes insipidus (68% vs. 51%, 
P = .03), of growth hormone deficiency (GHD) (93% vs. 
72%, P < .001) and of TSH deficiency (95% vs. 86%, 
P = .06) than patients with no DXA scan, and less often 
epilepsy (13% vs. 27%, P  =  .03) or a hydrocephalus 
(23% vs. 40%, P = .03). There was no difference in frac-
tures (18% vs. 18%, P = .95). The cohort consisted of 
93 AO CP (53%). There were 106 Dutch (60%) and 
71 Swedish (40%) patients included; 93 patients were 
men (53%) and 15 patients (8%) used medication for 
epilepsy. The median age at last follow-up was 45 years 
(range, 15-92). Median follow-up time was 16  years 
(range, 1-62). Mean body mass index (BMI) was 
31 ± 7 kg/m2 (range, 17-60) in all patients at last DXA 
scan (or, if DXA scans at adult age were unavailable, 
last available BMI) and was higher in women than in 
men (30 ± 6 vs. 33 ± 8 kg/m2, P = .02). CO CP had more 
often received radiotherapy as tumor treatment (66% 
vs. 38%, P < .001), had a higher occurrence of hydro-
cephalus (38% vs. 17%, P = .002) and epilepsy (26% 
vs. 12%, P = .01) than AO CP. In addition, CO CP had 
more often a GHD (92% vs. 79%, P  =  .02) and had 
higher occurrence of diabetes insipidus (77% vs. 52%, 
P < .001). Sex hormone replacement therapy was used in 
125 patients (94% of women aged 50 years or younger 
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and men with gonadal axis failure). In 2 patients, pres-
ence of GHD was unknown. In the GHD group, CO 
CP were more often using GH replacement therapy 
(GHRT) than AO CP (87% vs. 74%, P = .04). Five pa-
tients (3%) underwent bariatric surgery (1 gastric sleeve, 
4 gastric bypass); all of them were female. Of the 10 pa-
tients who were not treated with surgery, 5 had yttrium, 
1 was initially treated with radiation therapy, 1 had cyst 
aspiration, and the others were closely followed with 
imaging without therapy. The nonsurgery group had 
significant lower frequency of diabetes insipidus (10% 
vs. 67% in the entire cohort, P < .001), TSH deficiency 
(50% vs. 95%, P < .001), and trend toward lower visual 
deficiencies (50% vs. 78%, P = .09). Furthermore, BMI 
was not significantly different (P = .34). The tumor was 
described as stable during follow-up of these patients.
Fractures
Fractures occurred in 31 CP (18%). The fracture 
rate was 5.8 fractures per 1000 person-years. Mean 
age at last follow-up of patients who had fractures was 
52.0 ± 14.5 versus 45.5 ± 18.5 years in patients who 
had no fractures (P  =  .05). Mean follow-up time was 
16.8 ± 10.0 years of patients who had fractures versus 
18.6 ± 13.7 of patients who had no fractures (P = .60, 
n  =  135). Seven of the patients with fractures had 
osteopenia (70%); 4 had osteoporosis (40%) (at last 
DXA scan). Eight patients suffered from multiple frac-
tures (26%). The mean number of fractures per patient 
were 1.5 ± 1.1 (range, 1-6). The fracture types are de-
scribed in Table 2.
Fractures occurred more often in men than women 
(26% vs. 8%, P  =  .002), and men were less often 
treated with medication to improve BMD (7% vs. 18%, 
P = .02). A trend was seen toward a higher proportion 
of fractures in AO CP than in CO CP (23% vs. 12%, 
P = .06). There was no difference in percentage of pa-
tients with fractures between Dutch and Swedish pa-
tients (18% vs. 17%, P = .86).
Using a univariable logistic regression model 
investigating fractures, female sex (odds ratio [OR], 0.3; 
P = .004) and previous surgery (OR, 0.2; P = .01) were 
protective factors, whereas medication for epilepsy was 
identified as a risk factor (OR, 3.6; P = .03) (Table 3). 
Osteoporosis was not a significant independent factor 
(OR, 2.1; P = .21); for osteopenia, a trend was shown 
(OR, 2.6; P =  .09). There were 10 patients who never 
underwent surgery, of which 5 had a fracture; 26 of 
165 patients who did have surgery had a fracture. 
A trend was shown for radiotherapy as well, being pro-
tective to fractures (OR, 0.5; P = .06). When these in-
dependent variables were applied in the multivariable 
Table 1. Baseline Characteristics of the Included CP Survivors
All Survivors (n = 177)
Males 
(n = 93)
Females 
(n = 84)
P 
Value 
Age at last follow-up, ya 45 (15–92) 45 (16–92) 45 (15–82) .83
Age at presentation, ya 23 (0–79) 26 (0–79) 22 (4–73) .92
(Female/corresponding) gender, n (%) 84 (48%) 93 (53%) 84 (47%) .50
Childhood onset disease, n (%) 84 (48%) 44 (46%) 40 (48%) .97
Tumor location at 
presentation, n (%)
Intrasellar 6 (4%) 5 (5%) 1 (1%) .22
Suprasellar 69 (41%) 35 (52%) 34 (44%) .57
Intra-/suprasellar 95 (56%) 52 (57%) 43 (55%) .86
Craniopharyngioma treatment Surgery only 77 (44%) 42 (46%) 35 (42%) .55
Radiation only 2 (1%) 1 (1%) 1 (1%) 1.00
Surgery and radiation 88 (50%) 44 (48%) 44 (52%) .59
90Yttrium brachytherapy 23 (13%) 8 (9%) 15 (18%) .09
Pituitary deficiencies GH deficiencyb 149 (85%)/120 (81%) 78 (86%) 71 (85%) .83
TSH deficiencya 162 (92%)/161 (99%) 88 (95%) 74 (88%) .12
Hypogonadismb 155 (88%)/125 (94%) 84 (90%) 71 (85%) .24
Corticotrophic deficiencyb 146 (83%)/142 (99%) 81 (87%) 65 (77%) .09
ADH deficiencyb 113 (64%)/111 (98%) 61 (66%) 52 (61%) .61
Medical history Recurrence/progression 67 (39%) 33 (36%) 34 (41%) .53
Hypothalamic damage 63 (40%) 35 (42%) 28 (38%) .67
Hydrocephalus ever 47 (27%) 22 (24%) 25 (30%) .38
Visual impairment 125 (77%) 67 (41%) 58 (36%) .50
Epilepsy 33 (19%) 18 (19%) 15 (18%) .80
Diabetes mellitus 26 (15%) 11 (12%) 15 (18%) .26
BMD medication 21 (12%) 6 (7%) 15 (18%) .02
In 7 patients, tumor location at presentation was unknown. Bold values represent significant differences between males and females (P ≤ .05).
aMedian (range).
bAll/using replacement therapy.
Abbreviations: ADH, antidiuretic hormone; BMD medication, bone mineral density-increasing medication. 
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Cox regression model, the following hazard ratios were 
obtained: for sex 0.4 (95% confidence interval [CI], 0.2-
0.8, P = .02), for surgery 0.3 (0.1-0.8, P = .02) and for 
antiepileptic medication use 2.7 (1.1-6.7, P = .03) (-2LL 
χ 2  <  0.001, omnibus χ 2 0.001). Fracture-free survival 
curves are depicted in Fig. 1.
Low BMD values based on either T- or Z-scores was 
found in 11 patients (65%) with fractures as opposed 
to 32 patients (42%) without fractures in their history 
(P = .08) (35). Patients who had never been treated with 
surgery (n = 10) suffered from more fractures than pa-
tients who had been operated (50% vs. 16%, P = .006). 
A trend for more fractures was seen in patients who had 
never received radiotherapy compared with patients 
treated with radiotherapy (23% vs. 12%, P = .06).
Bone mineral density
Information on BMD is shown in Table 4. Mean age 
at last DXA scan is 44.8  ±  18.4  years. Overall mean 
BMD T- and Z-scores at last DXA scan were in the 
normal range: for example, for total body, femur neck, 
and L2-L4, the Z-scores were 0.1 ± 1.5 (range, -4.1 to 
3.5), -0.1 ± 1.3 (range, -2.7 to 4.7), and 0.0 ± 2.0 (range, 
-3.5 to 6.8), respectively (Table 4). However, low BMD 
in any of these sites was reported in 47 patients (50%) 
(whereas an SDS of -1 should correspond to a percentage 
of 16%). Scatter plots of BMD T- and Z-scores are shown 
in Fig. 2, showing a wide spread of SDS values also in 
patients with fractures. Osteoporosis occurred in 22 pa-
tients (24%) (Table 4). AO CP had a lower BMD of the 
femur (neck) than CO CP (0.92 ± 0.15 vs. 1.09 ± 0.28, 
P = .01) (Table 4) and a lower mean T-score of the femur 
(neck) (-0.8 ± 1.2 vs. 0.2 ± 2.1, P = .03), but compar-
able Z-scores. A trend was found for lower Z-score of 
the femur neck in males than in females (-0.4 ± 1.2 vs. 
0.2 ± 1.4, P =  .08). Of the patients with osteoporosis, 
19% has hypothalamic damage, as opposed to 36% of 
patients without osteoporosis (P = .15).
First, a univariable analysis for very low BMD/
osteoporosis was established: (borderline) significant 
contributors were age at DXA scan (OR, 1.032 [1.004-
1.063], P  =  .03), obstructive sleep apnea syndrome 
(OR, 2.9; 95% CI, 1.0-8.3; P  =  .05), and hydrocor-
tisone dose (OR, 1.1; 95% CI, 1.0-1.2; P  =  .06). 
After establishing a multivariable analysis, age (OR, 
1.03; 95% CI, 1.00-1.06; P  =  .03) was identified as 
a contributing independent prognostic factor (35). 
Hypothalamic damage did not contribute significantly 
to osteoporosis, nor did it contribute in a multivariable 
model for osteopenia when adjusted for age, medica-
tion to improve BMD and GHRT (OR, 1.6, P =  .49, 
model not significant).
Table 3. Univariable and Multivariable Logistic Regression Analysis for Determinants of Fractures in CP 
Survivors
Univariable Analysis
Multivariable Analysis 
(Nagelkerke R2 = 0.18)
Variables OR (95% CI) P OR (95% CI) P
Age at presentation 1.0 (0.99–1.0) .17   
Female sex 0.3 (0.1–0.6) .004 0.3 (0.1–0.7) .004
Adulthood onset disease 0.2 (1.0–4.9) .07   
Swedish cohort 0.9 (0.4–2.1) .86   
Surgery 0.2 (0.1–0.7) .01 0.1 (0.0–0.6) .009
Radiotherapy 0.5 (0.2–1.0) .06   
Hypothalamic damage 0.9 (0.4–2.0) .79   
Visual impairment 1.9 (0.6–5.9) .26   
Medication for epilepsy 3.6 (1.2–11.0) .03 3.0 (0.9–10.0) .07
Growth hormone deficiency 2.9 (0.6–13.0) .16   
GHRT 1.7 (0.7–4.3) .25   
Adrenal axis deficiency 0.9 (0.3–2.3) .77   
Hydrocortisone dose 1.0 (0.9–1.1) .95   
Gonadal axis deficiencya 2.3 (0.5–10.4) .28   
TSH deficiency 1.4 (0.3–6.6) .66   
Diabetes insipidus 1.2 (0.5–2.8) .62   
BMI 0.9 (0.9–1.0) .07   
Osteopenia 2.6 (0.9–7.7) .09   
Osteoporosis 2.1 (0.7–6.4) .21   
BMD increasing medication 2.1 (0.7–5.8) .17   
Age at last follow-up not included (violation of assumption of linearity of logit). Bold values represent significant variables (P ≤ .05). 
aReplacement therapy odds ratio, 1.6 (95% confidence interval, 0.7–4.0; P = .28)/after exclusion of postmenopausal females odds ratio, 1.3 (95% CI 
confidence interval, 0.4–4.2, P = .62). Hosmer Lemeshow P = .81, omnibus χ 2 <0.001. No subjects were excluded. Receiver operating characteristic 
area under the curve, 0.72.
Abbreviations: BMD, bone mineral density; BMI, body mass index; GHRT, GH replacement therapy.
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Final height
CP had a final height SDS within the normal range 
(Table 4). There were no differences in final height SDS 
between males and females (-0.3 ± 1.2 vs. -0.3 ± 1.2, 
P  =  .82) or between CO and AO CP (-0.3 ± 1.4 vs. 
-0.3 ± 1.0, P = .90).
Discussion
Eighteen percent of the CP had suffered from at least 
1 fracture during a median follow-up of 16  years. 
Fractures occurred more often in males than females and 
males were less often treated with medication intended 
to improve BMD, which could indicate that males were 
undertreated. DXA revealed overall mean BMD values 
in the normal range in our cohort and no differences in 
low BMD or T- or Z-scores between patients with and 
without fractures. However, the spread was wide: 46% 
had osteopenia and 24% had osteoporotic BMD T- or 
Z-scores.
In our study, osteoporosis was not a predictor of frac-
ture risk. Obviously, there are more factors than only 
BMD that contribute to fracture risk. In the literature, 
prior and current exposure to glucocorticoids was as-
sociated with an increased fracture risk of substantial 
importance beyond explanations by BMD (41). Using 
our logistic regression model for fractures, we did not 
find any role for pituitary hormonal deficiencies in 
the increased fracture rates. This is probably because 
of adequate replacement therapy, as illustrated by re-
placement rates of 94% for hypogonadotropic hypo-
gonadism. As expected, epilepsy medication accelerated 
fracture risk, whereas previous treatment with surgery 
and female sex were protective. Antiepileptic drugs can 
induce poor balance or clumsiness; certain antiepileptic 
drugs are associated with an increased rate of bone loss 
(17), and some may cause hyponatremia, which correl-
ates with fractures and low BMD (42).
The observation that surgery as previous tumor 
treatment was identified as a “protective” factor was 
surprising. Only a few patients were not treated with 
surgery; perhaps these are patients severely affected by 
comorbidities where surgery could not safely be per-
formed, thereby having an increased risk for fractures 
as well. Patients with a fracture in their history had a 
higher mean age, were more often male, and less often 
had surgery.
Female sex was observed to be a protective factor, 
which corresponds with the findings of Müller et  al. 
(24). This might be related to the relatively young age 
of our study population and to a higher BMI in women. 
In the premenopausal general population, higher fre-
quencies of fractures and lower osteoporosis preventive 
medication have been described in men, whereas in the 
postmenopausal general population, female sex is a risk 
factor for fractures (43–45).
A trend was shown for radiotherapy being protective 
for fractures. The general aim of the surgeons in treat-
ment of CP have shifted from attempting gross total re-
section toward aiming at a more limited resection today, 
which may leave more tumor mass behind and cause 
the need to additional treatment with radiotherapy. 
Presumably, the lower risk for fractures observed in our 
study is therefore explained by a less damaging treat-
ment strategy.
We found a high percentage of fractures in our study 
because the cumulative fracture incidence in a European 
population was reported to be 7.8% in men and 9.5% 
in women (19). In our previous study, no higher risk 
was found for fractures in our CP cohort (10). This may 
partly be related to a lack of reliable Dutch reference 
data, which prompted Wijnen et al. to compare fracture 
Figure 1. Fracture-free survival (Kaplan-Meier) curves. Multivariable 
Cox regression model hazard ratios: (A) sex 0.4 (95% CI, 0.2-
0.83; P = .02), (B) for surgery 0.32 (0.12-0.84; P = .02) and (C) 
for antiepileptics use 2.68 (1.08-6.69, P = 0.03) (-2LL χ 2 < 0.001, 
omnibus χ 2 0.001).
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incidence in Dutch patients with Swedish reference 
data. Fracture rate may differ between populations: 
it has been reported that Scandinavian countries have 
higher fracture rates than western Europe (46). Olsson 
et al. previously showed an increased fracture risk (1).
In a GHD population from the KIMS study  (Pfizer 
International Metabolic Database), fracture rates were 
reported to be even higher compared with our study 
(27% in males; 29% in females); no significant differ-
ences of fracture prevalence between patients with or 
without (multiple) other hormonal pituitary deficien-
cies were found (21). This suggests that GHD itself is 
an important factor in fracture risk, freestanding from 
other hormonal pituitary deficiencies. Given the high 
prevalence of GHD patients in our study, one might ex-
pect an even higher a frequency of fractures. Again, a 
demographic factor could play a role for a higher fre-
quency of fractures, or a registration bias, or compen-
sation of BMD by the protective factor of obesity in CP 
(47). Obesity occurred in up to 75% of our patients (34) 
and a trend was shown for BMI as protective factor for 
fractures in our univariate logistic regression analysis. 
Gonadal axis hormonal deficiency does not seem to be 
a major contributor for a higher frequency of fractures, 
as demonstrated by our results; probably because 94% 
of premenopausal women and men received hormonal 
replacement therapy.
The mean BMD at last DXA scan was normal in 
the total cohort, but low BMD occurred in 50% and 
osteoporosis in 24% (Table  4). The dispersion was 
rather large and similar in patients with and without 
fractures as showed in Fig.  1. BMD T- and Z-scores 
were similar between genders except for Z-score of 
the femur neck, which was lower in males (-0.4 ± 1.2 
vs. 0.2 ± 1.4, P =  .08). Sex or GHD were not a con-
tributing factor in our logistic regression model for 
osteoporosis.
Final height in our patients was not impaired: the 
mean SDS was -0.3 ± 1.2. It was also similar between 
AO CP and CO CP, and between genders. Apparently, 
GHRT had been sufficiently administered to these chil-
dren. Indeed, 87% of patients with CO CP and GHD 
received GHRT. This is different from the findings of 
Kendall-Taylor et al., who did find for AO CP a signifi-
cant difference in height (although it was on average 
only 3  cm or 0.6 SDS) (19). Perhaps the large size of 
their European cohort made it possible to find smaller 
differences, or there may be regional differences in 
treatment of CP, particularly the age at which GHRT 
is started.
Because of the retrospective cross-sectional de-
sign, there are some limitations of our study. Factors 
that may have contributed to a possible selection bias 
are the size and weight limitations of DXA scanners 
(48), DXA scans were performed based on individual 
care plan decided by the insight of the clinicians. All 
types of DXA scanners were included, whereas meas-
urements by different DXA scanners have shown 
intra-individual variability (49). However, agree-
ment between all DXA devices is high (50). By using 
age- and sex-matched SDS and applying generally 
used cutoffs to identify osteopenic or osteoporotic 
BMD values, we tried to limited the impact on our 
data. In our logistic regression model for osteopor-
osis, scanner type was not a contributing factor. 
Because of the retrospective design, relevant data on 
duration of GHRT, smoking, alcohol use, dietary in-
take, fractures of parents, physical activity, and level 
of 25-hydroxyvitamin D were lacking. The percentage 
of fractures could be underestimated because of a re-
porting bias. Still, since studies on bone health in CP 
are so limitedly available, our study provides more in-
sight and should create awareness for the importance 
of attention to bone health in CP.
Figure 2. Scatterplot of (A) T- and (B) Z-scores of bone mineral 
density of the femur neck, L2-L4, and total body in survivors of 
craniopharyngioma. The error bars express median and quartiles. 
Every circle or triangle represents a measurement at last dual X-ray 
absorptiometry scan. The red triangles represent patients who had 
fractures in the past; the gray circles represent patients who did not 
have fractures. A wide spread is shown in both patients with and 
without fractures in the past.
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This is the first study to date that investigated con-
tributory factors for fractures in CP and that describes 
bone health in a cohort existing of both CO and AO 
long-term survivors, with a large sample size. With this 
study, we hope to raise more awareness for the evalu-
ation of bone health. The decision to either or not per-
form a DXA scan is important in this respect, although 
DXA scans alone do not evaluate the quality of the bone 
or fracture risk sufficiently. Fracture rate could also be 
compromised by, for example, neurological defects. 
Nevertheless, clinicians should consider treatments that 
increase bone health, especially in males.
In conclusion, our cohort of CP showed a high 
frequency of fractures. Although men had a higher 
frequency of fractures, they received less frequent BMD-
increasing treatments. Pituitary hormone replacement 
therapy in our cohort overall seemed adequately man-
aged because pituitary hormonal deficiencies did not 
contribute significantly to fracture risk in our logistic 
regression model. Also of interest was our finding that 
osteoporotic BMD values did not predict the fracture 
risk. Our study suggests the importance of regularly 
evaluating fracture risk in every CP. We advise to take 
other risk factors than BMD into account, and suggest 
earlier evaluation of bone health increasing medication, 
especially in men.
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